BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 2010;12:928-40. [PMID: 21076618 DOI: 10.1593/neo.10804] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology 2023. [PMID: 36680397 DOI: 10.1097/HEP.0000000000000237] [Reference Citation Analysis]
2 Carcamo B, Francia G. Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature. J Clin Med 2022;11. [PMID: 35628975 DOI: 10.3390/jcm11102849] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chung MS, Han SJ. Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis. Front Glob Womens Health 2022;3:856316. [DOI: 10.3389/fgwh.2022.856316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bocci G, Banchi M, Garcia DG, Batson S, Francia G. Metronomic chemotherapy and antiangiogenic drugs: Preclinical and clinical data. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy 2022. [DOI: 10.1016/b978-0-323-90190-1.00017-2] [Reference Citation Analysis]
5 Suzuki H, Iwamoto H, Nakano M, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Kuromatsu R, Niizeki T, Okamura S, Shimose S, Shirono T, Noda Y, Kamachi N, Yano H, Kawaguchi A, Koga H, Torimura T. Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. Transl Oncol 2021;14:101201. [PMID: 34388691 DOI: 10.1016/j.tranon.2021.101201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 He Y, Luo Y, Huang L, Zhang D, Wang X, Ji J, Liang S. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Pharmacological Research 2021;170:105732. [DOI: 10.1016/j.phrs.2021.105732] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
7 Mastri M, Tracz A, Lee CR, Dolan M, Attwood K, Christensen JG, Liu S, Ebos JML. A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal. Cell Rep 2018;25:3706-3720.e8. [PMID: 30590043 DOI: 10.1016/j.celrep.2018.12.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
8 Muto H, Kuzuya T, Ito T, Ishizu Y, Honda T, Ishikawa T, Ishigami M, Fujishiro M. Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report. Clin J Gastroenterol 2020;13:397-402. [PMID: 31709503 DOI: 10.1007/s12328-019-01066-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Marin JJG, Herraez E, Lozano E, Macias RIR, Briz O. Models for Understanding Resistance to Chemotherapy in Liver Cancer. Cancers (Basel) 2019;11:E1677. [PMID: 31671735 DOI: 10.3390/cancers11111677] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
10 Azim HA, Omar A, Atef H, Zawahry H, Shaker MK, Abdelmaksoud AK, EzzElarab M, Abdel-Rahman O, Ismail M, Kassem L, Waked I. Sorafenib plus tegafur-uracil (UFT) vs sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). J Hepatocell Carcinoma. 2018;5:109-119. [PMID: 30510922 DOI: 10.2147/jhc.s169285] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Pukrop T, Herr W, Ghibelli L, Gerner C, Reichle A. Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue. Int J Mol Sci 2018;19:E3540. [PMID: 30424016 DOI: 10.3390/ijms19113540] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
12 Filippi R, Lombardi P, Depetris I, Fenocchio E, Quarà V, Chilà G, Aglietta M, Leone F. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. Expert Opin Pharmacother 2018;19:1451-63. [PMID: 30161003 DOI: 10.1080/14656566.2018.1512585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Saber S, Mahmoud A, Helal N, El-Ahwany E, Abdelghany R. Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice. Open Access Maced J Med Sci. 2018;6:955-960. [PMID: 29983784 DOI: 10.3889/oamjms.2018.167] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
14 Reguera-Nuñez E, Man S, Xu P, Kerbel RS. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models. Angiogenesis 2018;21:793-804. [PMID: 29786782 DOI: 10.1007/s10456-018-9623-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Mahli A, Saugspier M, Koch A, Sommer J, Dietrich P, Lee S, Thasler R, Schulze-Luehrmann J, Luehrmann A, Thasler WE, Müller M, Bosserhoff A, Hellerbrand C. ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis. Gut 2018;67:746-56. [PMID: 28053052 DOI: 10.1136/gutjnl-2016-312485] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
16 Xu G, Wang Y, Li W, Cao Y, Xu J, Hu Z, Hao Y, Hu L, Sun Y. COX-2 Forms Regulatory Loop with YAP to Promote Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells. Neoplasia. 2018;20:324-334. [PMID: 29505957 DOI: 10.1016/j.neo.2017.12.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
17 Ribatti D. Tumor refractoriness to anti-VEGF therapy. Oncotarget 2016;7:46668-77. [PMID: 27081695 DOI: 10.18632/oncotarget.8694] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 12.6] [Reference Citation Analysis]
18 Wang N, Jain RK, Batchelor TT. New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics 2017;14:321-32. [PMID: 28083806 DOI: 10.1007/s13311-016-0510-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
19 Dika IE, Abou-Alfa GK. Treatment options after sorafenib failure in patients with hepatocellular carcinoma. Clin Mol Hepatol 2017;23:273-9. [PMID: 29151326 DOI: 10.3350/cmh.2017.0108] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
20 Mastri M, Rosario S, Tracz A, Frink RE, Brekken RA, Ebos JM. The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy. Curr Drug Targets 2016;17:1747-54. [PMID: 26648063 DOI: 10.2174/1389450117666151209123544] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, Emmenegger U, Di Desidero T, Bocci G, Felder MS, Manciu M, Kirken RA, Francia G. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br J Cancer 2017;116:324-34. [PMID: 28056464 DOI: 10.1038/bjc.2016.429] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
22 Tridente G. Sorafenib. Adverse Events and Oncotargeted Kinase Inhibitors 2017. [DOI: 10.1016/b978-0-12-809400-6.00008-1] [Reference Citation Analysis]
23 Wang N, Kloepper J, Jain RK, Batchelor TT. Antiangiogenic Therapy for Malignant Gliomas. Malignant Brain Tumors 2017. [DOI: 10.1007/978-3-319-49864-5_11] [Reference Citation Analysis]
24 Wragg JW, Heath VL, Bicknell R. Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors. Cancer Res 2017;77:1008-20. [PMID: 28011623 DOI: 10.1158/0008-5472.CAN-16-1982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
25 Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet 2016;388:518-29. [PMID: 26853587 DOI: 10.1016/S0140-6736(15)01088-0] [Cited by in Crossref: 537] [Cited by in F6Publishing: 562] [Article Influence: 76.7] [Reference Citation Analysis]
26 Kerbel RS. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. Cancer J 2015;21:274-83. [PMID: 26222079 DOI: 10.1097/PPO.0000000000000134] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
27 Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. J Natl Cancer Inst 2016;108. [PMID: 27059374 DOI: 10.1093/jnci/djw030] [Cited by in Crossref: 104] [Cited by in F6Publishing: 112] [Article Influence: 14.9] [Reference Citation Analysis]
28 Mirone G, Perna S, Marfe G. Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance to Targeted Anti-Cancer Therapeutics 2016. [DOI: 10.1007/978-3-319-46091-8_2] [Reference Citation Analysis]
29 Kuczynski EA, Lee CR, Man S, Chen E, Kerbel RS. Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Res 2015;75:2510-9. [PMID: 25908587 DOI: 10.1158/0008-5472.CAN-14-3687] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 6.4] [Reference Citation Analysis]
30 Riganti C, Gazzano E, Gulino GR, Volante M, Ghigo D, Kopecka J. Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. Cancer Lett 2015;360:219-26. [PMID: 25681670 DOI: 10.1016/j.canlet.2015.02.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
31 Caviglia JM, Schwabe RF. Mouse models of liver cancer. Methods Mol Biol 2015;1267:165-83. [PMID: 25636469 DOI: 10.1007/978-1-4939-2297-0_8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
32 Digklia A, Voutsadakis IA. Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. World J Exp Med 2014; 4(4): 58-67 [PMID: 25414818 DOI: 10.5493/wjem.v4.i4.58] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
33 Ahmadi M, Ahmadihosseini Z, Allison SJ, Begum S, Rockley K, Sadiq M, Chintamaneni S, Lokwani R, Hughes N, Phillips RM. Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors. Br J Pharmacol 2014;171:224-36. [PMID: 24117380 DOI: 10.1111/bph.12438] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
34 Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Neoplasia. 2014;16:595-605. [PMID: 25047655 DOI: 10.1016/j.neo.2014.06.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
35 Nam SW, Park KC, Choi HS, Lee B, Kim SW. Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines. J Gastroenterol Hepatol 2014;29:633-9. [PMID: 24716227 DOI: 10.1111/jgh.12414] [Reference Citation Analysis]
36 Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol 2014;41:235-51. [PMID: 24787295 DOI: 10.1053/j.seminoncol.2014.02.007] [Cited by in Crossref: 82] [Cited by in F6Publishing: 96] [Article Influence: 9.1] [Reference Citation Analysis]
37 Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471-94. [PMID: 24482243 DOI: 10.1007/s10456-014-9420-y] [Cited by in Crossref: 474] [Cited by in F6Publishing: 430] [Article Influence: 52.7] [Reference Citation Analysis]
38 Shao Y, Cheng A, Hsu C. Clinical Activity of Metronomic Chemotherapy in Liver Cancers. Metronomic Chemotherapy 2014. [DOI: 10.1007/978-3-662-43604-2_13] [Reference Citation Analysis]
39 Vives M, Laquente B, Viñals F. Preclinical Activity of Metronomic Regimens with Alkylating Agents and Antimetabolites. Metronomic Chemotherapy 2014. [DOI: 10.1007/978-3-662-43604-2_4] [Reference Citation Analysis]
40 Caviglia J, Schwabe R. Experimental Hepatocarcinogenesis. Pathobiology of Human Disease 2014. [DOI: 10.1016/b978-0-12-386456-7.04212-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 He AR, Goldenberg AS. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap Adv Gastroenterol 2013;6:447-58. [PMID: 24179481 DOI: 10.1177/1756283X13498540] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
42 Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013;6:511-9. [PMID: 24151531 DOI: 10.1593/tlo.13481] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
43 Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol 2013;10:571-87. [PMID: 23999218 DOI: 10.1038/nrclinonc.2013.158] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
44 Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol 2013;10:571-87. [PMID: 23999218 DOI: 10.1038/nrclinonc.2013.158] [Cited by in Crossref: 171] [Cited by in F6Publishing: 184] [Article Influence: 17.1] [Reference Citation Analysis]
45 Jin F, Gao D, Wu Q, Liu F, Chen Y, Tan C, Jiang Y. Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor. Bioorganic & Medicinal Chemistry 2013;21:5694-706. [DOI: 10.1016/j.bmc.2013.07.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
46 Rehemtulla A. Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia 2012;14:1278-89. [PMID: 23308059 DOI: 10.1593/neo.122096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
47 De Minicis S, Kisseleva T, Francis H, Baroni GS, Benedetti A, Brenner D, Alvaro D, Alpini G, Marzioni M. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis 2013;45:450-9. [PMID: 23177172 DOI: 10.1016/j.dld.2012.10.008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 6.8] [Reference Citation Analysis]
48 Cuconati A, Mills C, Goddard C, Zhang X, Yu W, Guo H, Xu X, Block TM. Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells. PLoS One 2013;8:e54595. [PMID: 23355882 DOI: 10.1371/journal.pone.0054595] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
49 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
50 Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 2012;56:686-95. [PMID: 21971559 DOI: 10.1016/j.jhep.2011.07.031] [Cited by in Crossref: 131] [Cited by in F6Publishing: 143] [Article Influence: 11.9] [Reference Citation Analysis]
51 Nukatsuka M, Saito H, Nakagawa F, Tsujimoto H, Sakamoto K, Tsukioka S, Uchida J, Kiniwa M, Kobunai T, Takechi T. Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice. Exp Ther Med 2012;3:755-62. [PMID: 22969964 DOI: 10.3892/etm.2012.484] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
52 Shao YY, Lin ZZ, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH, Cheng AL. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology. 2012;82:59-66. [PMID: 22310088 DOI: 10.1159/000336126] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
53 Rehemtulla A. The interconnectedness of cancer cell signaling. Neoplasia 2011;13:1183-93. [PMID: 22241964 DOI: 10.1593/neo.111746] [Reference Citation Analysis]
54 Calvani N, Morelli F, Leo S, Orlando L, Lombardi L, Gnoni A, Cinefra M, Maiello E, Lorusso V, Cinieri S. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol 2012;29:1908-13. [DOI: 10.1007/s12032-011-0048-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
55 Gordon MS. Antiangiogenic therapies: is VEGF-A inhibition alone enough? Expert Rev Anticancer Ther 2011;11:485-96. [PMID: 21417860 DOI: 10.1586/era.11.5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
56 Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One 2011;6:e19144. [PMID: 21559452 DOI: 10.1371/journal.pone.0019144] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 5.1] [Reference Citation Analysis]
57 Rehemtulla A. Dinosaurs and ancient civilizations: reflections on the treatment of cancer. Neoplasia 2010;12:957-68. [PMID: 21170260 DOI: 10.1593/neo.101588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]